Abeona Therapeutics names Mohamad Tabrizi as chief business officer Dec 15, 2025 07:31AM
Abeona Therapeutics (ABEO) Announces Additional Phase 3 VIITAL Study Results for EB-101 May 11, 2023 07:02AM
Abeona Therapeutics (ABEO) Announces Positive Topline Results with Both Co-Primary Endpoints Met in Pivotal Phase 3 VIITAL Study of EB-101 Nov 3, 2022 07:30AM
Abeona Therapeutics (ABEO) Issues Letter to Stockholders May 26, 2021 07:38AM
Abeona Therapeutics (ABEO) Reports Successful Type B Meeting with FDA for Pivotal Phase 3 VIITAL Study of EB-101 in RDEB Jan 25, 2021 07:33AM


Jul 10, 2020 07:34AM Abeona Therapeutics (ABEO) Announces Two Presentations Related to Its RDEB Clinical Program at SPD
Jul 8, 2020 07:31AM Abeona Therapeutics (ABEO) Resumes Enrollment in EB-101 Pivotal Phase 3 VIITAL Study in RDEB; Reports Progress in Patient Enrollment in MPS III Studies
Mar 17, 2020 07:31AM Abeona Therapeutics (ABEO) Reports First Patient Treatment in Pivotal Phase III Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
Jan 13, 2020 09:03AM Abeona Therapeutics (ABEO) Begins Phase 3 Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
Dec 9, 2019 08:50AM Abeona Therapeutics (ABEO) announced FDA has removed its clinical hold and provided clearance to proceed with the VIITAL study
Oct 15, 2019 09:17AM Abeona Therapeutics (ABEO) Announces Publication of Positive Long-Term Data from Phase 1/2a Clinical Trial Evaluating EB-101 Gene Therapy for RDEB
May 17, 2018 09:21AM Abeona Therapeutics (ABEO) Updates Clinical Data from Phase 1/2 Trial for EB-101 Gene Therapy in Epidermolysis Bullosa
May 14, 2018 08:16AM Abeona Therapeutics (ABEO) Announces Appointment of Stefano Buono and Richard Van Duyne to its Board of Directors
Jul 18, 2017 08:08AM Abeona Therapeutics (ABEO) Announces Guidance from FDA to Commence Pivotal Phase 3 for EB-101 Gene Therapy for Patients with Epidermolysis Bullosa
May 30, 2017 08:06AM Abeona Therapeutics (ABEO) Granted Rare Pediatric Disease Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa
May 2, 2017 08:07AM Abeona Therapeutics (ABEO) Provides Update from Ongoing Phase 1/2 Trial of EB-101 Gene Therapy for Severe Form of Epidermolysis Bullosa
Mar 8, 2017 08:19AM Abeona Therapeutics (ABEO) Announces EU Orphan Drug Designation for EB-101 Gene Therapy Clinical Trial for Epidermolysis Bullosa
Nov 2, 2016 08:08AM Abeona Therapeutics (ABEO) Announces Publication of Positive EB-101 Phase 1 Data; Says Well-Tolerated in RDEB
Oct 14, 2016 07:03AM Abeona Therapeutics (ABEO) Announces Presentation of ABO-102 Phase 1/2 data in MPS IIA
Oct 6, 2015 09:04AM Abeona Therapeutics (ABEO) Enters License for AAV Delivery Vector for FA Treatment